Table 1 Selected patient and tumor characteristics
Characteristics | Total (NÂ =Â 819) |
|---|---|
N (%) | |
Age (in years) | |
 <50 | 348 (42.5) |
 ≥50 | 471 (57.5) |
NPI score | |
 Median (range) | 5.52 (3.0–9.0) |
Treatment group | |
 E-CMF | 123 (15.0) |
 E-T-CMF | 392 (47.9) |
 ET-CMF | 304 (37.1) |
Menopausal status | |
 Premenopausal | 375 (45.8) |
 Postmenopausal | 444 (54.2) |
Breast surgery | |
 Modified radical mastectomy | 579 (70.7) |
 Breast-conserving surgery | 240 (29.3) |
ER/PgR status | |
 Negative | 165 (21.7) |
 Positive | 596 (78.3) |
Histological grade | |
 I–II | 406 (49.6) |
 III–Undifferentiated | 413 (50.4) |
Tumor size (cm) | |
 ≤2 | 181 (22.8) |
 2–5 | 517 (65.2) |
 >5 | 95 (12.0) |
Positive lymph nodes | |
 1–3 nodes | 331 (40.5) |
 ≥4 nodes | 487 (59.5) |
Adjuvant radiation therapy | |
 No | 184 (23.2) |
 Yes | 609 (76.8) |
Adjuvant hormonal therapy | |
 No | 154 (18.9) |
 Yes | 661 (81.1) |
Bone metastases | |
 No | 711 (88.4) |
 Yes | 93 (11.6) |
HER2 status | |
 Negative | 593 (76.5) |
 Positive | 182 (23.5) |
Ki67 protein expression | |
 Low (<20%) | 367 (44.8) |
 High (≥20%) | 452 (55.2) |
Subtypes | |
 Luminal A | 245 (32.3) |
 Luminal B | 248 (32.8) |
 Luminal-HER2 | 99 (13.1) |
 HER2-enriched | 79 (10.4) |
 Triple-negative | 86 (11.4) |
OPN mRNA expression | |
 Low (<50th percentile) | 407 (50.0) |
 High (≥50th percentile) | 407 (50.0) |
OPN protein expression | |
 Low (0–4 Allred score) | 59 (10.8) |
 High (5–8 Allred score) | 487 (89.2) |